Get the Stockscreener App
6.06
0.16%
-0.01
After Hours:
5.93
-0.13
-2.15%
Coya Therapeutics Inc stock is traded at $6.06, with a volume of 32,244.
It is down -0.16% in the last 24 hours and up +0.17% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$6.07
Open:
$6.17
24h Volume:
32,244
Relative Volume:
0.42
Market Cap:
$101.35M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-6.1837
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
-6.77%
1M Performance:
+0.17%
6M Performance:
+17.21%
1Y Performance:
-14.04%
1-Day Range:
$5.94
$6.17
1-Week Range:
$5.94
$6.70
52-Week Range:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.06 | 101.52M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
News impact scoring models applied to Coya Therapeutics Inc.2025 Investor Takeaways & Daily Price Action Insights - newser.com
Will Coya Therapeutics Inc. stock go up soonQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Will Coya Therapeutics Inc. stock deliver better than expected guidanceEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Published on: 2025-10-13 10:06:24 - newser.com
When is the best time to exit Coya Therapeutics Inc.Trade Signal Summary & Expert Approved Momentum Ideas - newser.com
Should you hold or exit Coya Therapeutics Inc. nowQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Best data tools to analyze Coya Therapeutics Inc. stock2025 Market Sentiment & Breakout Confirmation Alerts - newser.com
Reversal indicators forming on Coya Therapeutics Inc. stockLong Setup & AI Enhanced Market Trend Forecasts - newser.com
Is Coya Therapeutics Inc. stock poised for growthTrade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Is now a turning point for Coya Therapeutics Inc.Portfolio Return Summary & Precise Buy Zone Tips - newser.com
What data driven models say about Coya Therapeutics Inc.’s futureBreakout Watch & Daily Chart Pattern Signal Reports - newser.com
Candlestick signals on Coya Therapeutics Inc. stock todayQuarterly Profit Review & Safe Entry Trade Reports - newser.com
Quantitative breakdown of Coya Therapeutics Inc. recent move2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
What momentum shifts mean for Coya Therapeutics Inc.Quarterly Investment Review & Low Volatility Stock Suggestions - newser.com
Coya Therapeutics (NASDAQ:COYA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-09 03:57:14 - newser.com
Ranking Coya Therapeutics Inc. among high performing stocks via tools2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - BioSpace
What analysts say about Coya Therapeutics Inc stockPrice Momentum Alerts & Budget Friendly Portfolio Growth - earlytimes.in
Predicting Coya Therapeutics Inc. trend using moving averages2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
What sentiment indicators say about Coya Therapeutics Inc. stockWeekly Risk Report & Community Consensus Picks - newser.com
How to integrate Coya Therapeutics Inc. into portfolio analysis toolsWeekly Trading Summary & Stock Portfolio Risk Management - newser.com
Will Coya Therapeutics Inc. stock outperform value stocksPrice Action & Risk Controlled Daily Trade Plans - newser.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.20 Consensus PT from Analysts - Defense World
What drives Coya Therapeutics Inc stock priceDividend Yield Trends & Trusted Financial Advisors at No Cost - earlytimes.in
BTIG Reiterates Buy Rating on COYA with $15 Price Target | COYA Stock News - GuruFocus
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from BTIG Research - MarketBeat
Positive Outlook for Coya Therapeutics Driven by Promising COYA-302 Clinical Developments and Regulatory Support - TipRanks
Coya completes FTD combination therapy trial enrolment - Yahoo Finance
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - Quantisnow
COYA Stock Analyst Rating: D. Boral Capital Maintains "Buy" Rati - GuruFocus
Coya Therapeutics' (COYA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Coya Therapeutics announces completion of patient enrollment - MarketScreener
Promising Dementia Treatment Trial: Coya Therapeutics Completes Key FTD Study Enrollment with Zero Safety Issues - Stock Titan
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Coya Therapeutics Inc Stock (COYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SNYDER DAVID S | Chief Financial Officer |
Nov 14 '24 |
Buy |
7.19 |
1,800 |
12,934 |
8,800 |
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):